retatrutide weight loss phase 2 results VisualAbstract: reduces body by 17.5% in patients with obesity The New Gold Standard: Retatrutide

Any future retatrutide prescribing guidance would define its own stopping criteria in its Summary of Product Characteristics (SmPC) and any relevant NICE technology appraisal, if licensed

Retatrutide is an investigational triple agonist peptide designed to activate GLP-1, GIP and glucagon receptors

Beyond weight loss, GLP-1 agonists have demonstrated the ability to reduce major cardiovascular events, combat fatty liver disease, and alleviate obesity-related complications such as knee pain, sleep apnea, and acid reflux

Cell-based assays and animal studies also report changes in gene expression linked to anabolic signaling, lipid metabolism, and cellular repair processes